HemaSphere (Jun 2022)

P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN

  • C. Rodriguez,
  • J. L. Kaufman,
  • J. Laubach,
  • D. W. Sborov,
  • B. Reeves,
  • A. Chari,
  • R. Silbermann,
  • L. J. Costa,
  • L. D. Anderson, Jr,
  • N. Nathwani,
  • N. Shah,
  • N. Bumma,
  • A. Jakubowiak,
  • R. Z. Orlowski,
  • H. Pei,
  • A. Cortoos,
  • S. Patel,
  • T. S. Lin,
  • P. G. Richardson,
  • P. M. Voorhees

DOI
https://doi.org/10.1097/01.HS9.0000846604.67185.0c
Journal volume & issue
Vol. 6
pp. 824 – 825

Abstract

Read online

No abstracts available.